BrandWikiReturn

Intas Pharmaceuticals

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad.[2] It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing.[3] It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico.[1] In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India.[4] Its market presence is in more than 100+ countries.

History

The company was founded by a Jain pharmacist Hasmukh Chudgar in 1977[5] and was incorporated in 1985.[6]

In 2013, ChrysCapital acquired 16.14% stake in the company, and in 2015, ChrysCapital subsequently sold 10.13% to Singapore-based Temasek Holdings[7] and in 2017, it further diluted 3.01% stake to Capital International. Though, by May 2020, ChrysCapital bought back Capital International's stake.[8] Currently, the Chudgar family, owns 83.85% stake in the company, with 10.13% being held by Temasek Holdings, and 6.02% by ChrysCapital.[6]

As of March 2021, the company is operating 19 manufacturing facilities globally - 13 in India, 5 in the UK, and 1 in Mexico.[6] The company has set up a new manufacturing facility in PHARMEZ (Bavla, near Ahmedabad) with capacity to manufacture and export more than 1 billion solid dosages and 5 million injectables.[9]

Divisions

Biologics Unit (formerly, Intas Biopharmaceuticals)

In 2000, an independent biotechnology division of Intas Pharmaceuticals was incorporated as Intas Biopharmaceuticals by Urmish Chudgar, a hematologist. Later in 2012–13, the subsidiary was merged with the parent company Intas Pharmaceuticals Limited.[10] This division is involved in development and manufacturing of biosimilar products based on recombinant DNA and monoclonal antibodies.[11]

The company underwent an EU GMP (Good Manufacturing Practice) audit in December 2006 to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU GMP-compliant in April 2007, becoming the first company in India to receive such certification.[12] In 2015, the company launched its first biosimilar product, Filgrastim in Europe, to treat patients with advanced HIV infection and immune system disorders such as neutropenia.[13][14]

Apart from EU GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.[15]

Subsidiaries

Accord Healthcare

London-headquartered Accord Healthcare is a fully owned subsidiary of Intas Pharmaceuticals, which deals with large-scale generic pharmaceuticals across Europe and North America markets. It also manages an American R&D unit which is located at Research Triangle Park, Durham. As of 2018, the company has approval for 89 Abbreviated New Drug Applications and is selling 255 dosing presentations.[16]

Acquisitions

Teva Pharmaceuticals (UK & Ireland)

In 2016, Intas acquired the assets of Teva Pharmaceuticals in the UK and Ireland for US$764 million.[17][2]

Actavis (UK & Ireland)

In 2017, the company's Accord Healthcare announced acquisition of Actavis UK Ltd. and Actavis Ireland Ltd from Teva Pharmaceutical Industries, for an enterprise value of £603 million.[18][19] The deal included a portfolio of generic medicines and a manufacturing plant in Barnstaple.[20]

Sanofi's Fawdon Plant

In 2018, Intas' subsidiary Accord Healthcare reopened Sanofi's Fawdon plant in the UK for manufacturing generic effervescent medicines. The plant was acquired in 2015 after Sanofi closed the facility.[21] This is the fifth manufacturing location for Accord in the country after Harrow, Barnstaple, Haverhill, and Didcot.[22]

Controversies

In December 2020, Intas Pharmaceuticals, along with Mankind Pharma, received show-cause notices for selling an anti-diabetic medicine without obtaining mandatory price approval from the National Pharmaceutical Pricing Authority.[23]

In December 2022, a U.S. FDA inspection found that Intas's manufacturing plant in Sanand, India, was intentionally falsifying laboratory data and destroying critical quality-control records. Inspectors documented a truckload of shredded test records and multiple instances of manipulated results, raising concerns about the reliability of the potency and purity of drugs released from the facility.[24]

In 2023, testing conducted on behalf of the American military by the independent laboratory Valisure found that generic tacrolimus produced by Intas did not perform as an equivalent substitute for the brand-name version, adding to concerns about quality control at the company.[25] Another study in 2015 had concluded that tacrolimus produced by Accord did not work as intended, yet it remained on the market.[26]

See also

External links

References

  1. Intas Pharmaceuticals Limited ICRA, retrieved 26 September 2025^
  2. Vikas Dandekar, Arijit Barman. Chudgars of Intas: A family that dreams big together The Economic Times, 7 October 2016^
  3. Bhuma Shrivastava. Intas Pharma may offload 10% to raise Rs200 cr from market mint, 29 September 2007, retrieved 9 February 2023^
  4. Financials – Intas Pharmaceuticals Ltd. Intas Pharmaceuticals Ltd., retrieved 1 January 2022^
  5. Hasmukh Chudgar & family Forbes, retrieved 2021-10-03^
  6. Shamsher Dewan, Kinjal Shah, Gaurav Jain, Vanshika Gupta. Intas Pharmaceuticals Limited: Long-term rating upgraded to [ICRA]AA+ (Stable); shortterm rating reaffirmed ICRA Limited, 19 July 2021, retrieved 3 October 2021^
  7. Pooja Sarkar. Temasek pumps more than Rs4,600 crore into India in Q1 mint, 2015-07-10, retrieved 2021-10-03^
  8. Madhav Chanchani. ChrysCapital backs Intas again, buys 3%, valuation hits $4.3 billion The Times of India, 2 June 2020, retrieved 2021-10-03^
  9. Krunal Modi, Ranjan Sharma. Analyst Report - Intas Pharmaceuticals Limited, March 11, 2021 CARE Ratings, 11 March 2021, retrieved 2021-10-03^
  10. Chitra Unnithan. Intas Pharmaceuticals: Intas Pharma merges group companies, subsidiaries The Times of India, 18 June 2012, retrieved 2021-10-03^
  11. Sujay Shetty, Nisha Vishwakarma. Global pharma looks to India: Prospects for growth PricewaterhouseCoopers, retrieved 2021-10-03^
  12. Intas mfg unit gets EU-GMP certification The Economic Times, 13 June 2007, retrieved 2021-10-03^
  13. Ramnath Subbu. Intas Pharma launches biosimilar in Europe The Hindu, 2015-02-23, retrieved 2021-10-03^
  14. Intas Pharmaceuticals launches biosimilar in Europe The Financial Express, 2015-03-06, retrieved 2021-10-03^
  15. Intas's Growth Driver : Biopharmaceuticals NCK Pharma, 2015-01-23, retrieved 2021-10-03^
  16. Accord Healthcare Inc August 9, 2018 Pharmacy Times, 9 August 2018, retrieved 2021-10-03^
  17. Vikas Dandekar, Arijit Barman. Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club The Economic Times, 2016-10-06, retrieved 2020-05-08^
  18. Intas Pharmaceuticals Completes Deal to Acquire Actavis Moneycontrol, retrieved 2020-05-08^
  19. Intas to acquire UK & Ireland generics businesses from Teva for £603 million @businessline, 5 October 2016, retrieved 2021-07-04^
  20. Shraddha Babla. Intas Pharma In No Hurry To List, Says MD Binish Chudgar BloombergQuint, 7 October 2016, retrieved 2021-10-03^
  21. Flora Southey. Intas puts the fizz back into ex-Sanofi plant with generic effervescents Outsourcing-Pharma.com, 31 January 2018^
  22. 500 jobs to be created by Accord Healthcare at its new Fawdon Pharmaceutical Factory Invest North East England, 2018-01-25, retrieved 2021-10-03^
  23. Himani Chandna. Mankind Pharma, Intas found selling diabetes drug 'without nod', to get show cause notice ThePrint, 31 December 2020, retrieved 2021-10-03^
  24. Compliance Record: Intas Pharmaceuticals Food and Drug Administration^
  25. Anna Edney, Riley Griffin. The Pentagon Wants to Root Out Shoddy Drugs. The FDA Is In Its Way. Bloomberg.com, 5 December 2023, retrieved 5 December 2023^
  26. Megan Rose, Debbie Cenziper. Fighting for Breath ProPublica, 19 December 2025, retrieved 25 December 2025^